These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21225894)

  • 1. A Bayesian subgroup analysis with a zero-enriched Polya Urn scheme.
    Sivaganesan S; Laud PW; Müller P
    Stat Med; 2011 Feb; 30(4):312-23. PubMed ID: 21225894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian subgroup analysis using collections of ANOVA models.
    Liu J; Sivaganesan S; Laud PW; Müller P
    Biom J; 2017 Jul; 59(4):746-766. PubMed ID: 28319254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test.
    Doi M; Takahashi F; Kawasaki Y
    Stat Med; 2017 Dec; 36(30):4789-4803. PubMed ID: 28960376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian designs with frequentist and Bayesian error rate considerations.
    Wang YG; Leung DH; Li M; Tan SB
    Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian approach to non-inferiority trials for normal means.
    Gamalo MA; Wu R; Tiwari RC
    Stat Methods Med Res; 2016 Feb; 25(1):221-40. PubMed ID: 22619277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian inference of P(π1 > π2) for two proportions.
    Kawasaki Y; Miyaoka E
    J Biopharm Stat; 2012; 22(3):425-37. PubMed ID: 22416833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian hypothesis testing in two-arm trials with dichotomous outcomes.
    Zaslavsky BG
    Biometrics; 2013 Mar; 69(1):157-63. PubMed ID: 23002906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting qualitative interaction: a Bayesian approach.
    Bayman EO; Chaloner K; Cowles MK
    Stat Med; 2010 Feb; 29(4):455-63. PubMed ID: 19950107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size estimation in single-arm clinical trials with multiple testing under frequentist and Bayesian approaches.
    Zaslavsky BG; Scott J
    J Biopharm Stat; 2012; 22(4):819-35. PubMed ID: 22651117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment.
    Biau DJ; Boulezaz S; Casabianca L; Hamadouche M; Anract P; Chevret S
    BMC Med Res Methodol; 2017 Aug; 17(1):128. PubMed ID: 28830464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacing P-values with frequentist posterior probabilities of replication-When possible parameter values must have uniform marginal prior probabilities.
    Llewelyn H
    PLoS One; 2019; 14(2):e0212302. PubMed ID: 30811495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian approach on sample size calculation for comparing means.
    Wang H; Chow SC; Chen M
    J Biopharm Stat; 2005; 15(5):799-807. PubMed ID: 16078386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monte Carlo approaches to frequentist multiplicity-adjusted benefiting subgroup identification.
    Schnell PM
    Stat Methods Med Res; 2021 Apr; 30(4):1026-1041. PubMed ID: 33256562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.